BR9812727A - Preparação e uso de ácidos orto-sulfonamido bicìclico hetero aril hidroxâmicos como metalo proteinase matriz e inibidores de tace - Google Patents
Preparação e uso de ácidos orto-sulfonamido bicìclico hetero aril hidroxâmicos como metalo proteinase matriz e inibidores de taceInfo
- Publication number
- BR9812727A BR9812727A BR9812727-6A BR9812727A BR9812727A BR 9812727 A BR9812727 A BR 9812727A BR 9812727 A BR9812727 A BR 9812727A BR 9812727 A BR9812727 A BR 9812727A
- Authority
- BR
- Brazil
- Prior art keywords
- carbon atoms
- alkyl
- carbon
- phenyl
- ring
- Prior art date
Links
- 125000001072 heteroaryl group Chemical group 0.000 title abstract 7
- 102000035195 Peptidases Human genes 0.000 title abstract 2
- 108091005804 Peptidases Proteins 0.000 title abstract 2
- 239000011159 matrix material Substances 0.000 title abstract 2
- 239000002184 metal Substances 0.000 title abstract 2
- 229910052751 metal Inorganic materials 0.000 title abstract 2
- 235000019833 protease Nutrition 0.000 title abstract 2
- 239000002447 tumor necrosis factor alpha converting enzyme inhibitor Substances 0.000 title abstract 2
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 17
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 abstract 5
- 229910052799 carbon Inorganic materials 0.000 abstract 5
- 229910052757 nitrogen Inorganic materials 0.000 abstract 5
- 125000003342 alkenyl group Chemical group 0.000 abstract 4
- 125000000304 alkynyl group Chemical group 0.000 abstract 4
- 125000005842 heteroatom Chemical group 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 229910052717 sulfur Chemical group 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical group [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 abstract 3
- 239000001257 hydrogen Substances 0.000 abstract 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 3
- 239000001301 oxygen Chemical group 0.000 abstract 3
- 239000011593 sulfur Chemical group 0.000 abstract 3
- NEAQRZUHTPSBBM-UHFFFAOYSA-N 2-hydroxy-3,3-dimethyl-7-nitro-4h-isoquinolin-1-one Chemical compound C1=C([N+]([O-])=O)C=C2C(=O)N(O)C(C)(C)CC2=C1 NEAQRZUHTPSBBM-UHFFFAOYSA-N 0.000 abstract 2
- 102000004190 Enzymes Human genes 0.000 abstract 2
- 108090000790 Enzymes Proteins 0.000 abstract 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 abstract 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 abstract 2
- 125000001624 naphthyl group Chemical group 0.000 abstract 2
- 125000006413 ring segment Chemical group 0.000 abstract 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 abstract 1
- 102000002274 Matrix Metalloproteinases Human genes 0.000 abstract 1
- 108010000684 Matrix Metalloproteinases Proteins 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 150000007513 acids Chemical class 0.000 abstract 1
- 125000004429 atom Chemical group 0.000 abstract 1
- BFPSDSIWYFKGBC-UHFFFAOYSA-N chlorotrianisene Chemical compound C1=CC(OC)=CC=C1C(Cl)=C(C=1C=CC(OC)=CC=1)C1=CC=C(OC)C=C1 BFPSDSIWYFKGBC-UHFFFAOYSA-N 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 125000004404 heteroalkyl group Chemical group 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229920006395 saturated elastomer Polymers 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/48—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D215/54—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Vascular Medicine (AREA)
- AIDS & HIV (AREA)
- Emergency Medicine (AREA)
- Molecular Biology (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Pain & Pain Management (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Patente de Invenção: <B>"PREPARAçãO E USO DE áCIDOS ORTO-SULFONAMIDO BICìCLICO HETERO ARIL HIDROXâMICOS COMO METALO PROTEINASE MATRIZ E INIBIDORES DE TACE"<D>. Esta invenção provê inibidores não-peptídios de baixo peso molecular de metaloproteinase matriz e enzima convertendo TNF-alfa (TACE, enzima convertendo fator-alfa de necrose de tumor) de fórmula (B) onde (B) é (1), (2), e (3); P e Q são (4) ou (5); contanto que quando P é (4), Q é (5), e vice-versa; T, U, W, e X são cada, independentemente, carbono ou nitrogênio, contanto que quando T ou U é carbono, qualquer pode opcionalmente estar substituído com R^ 1^; Y é carbono, nitrogênio, oxigênio ou enxofre, contanto que pelo menos um de T, U, W, X, e Y não seja carbono, e ainda contanto que não mais que 2 de T, U, W, e X sejam nitrogênio; (6) é um anel fenila ou é um anel hetero arila de 5-6 átomos de anel que pode conter 0-2 heteroátomos selecionados de nitrogênio, oxigênio, e enxofre, em adição a quaisquer heteroátomos definidos por W ou X; onde o anel fenila ou hetero arila pode estar opcionalmente mono-, di-, ou tri-substituído com R^ 1^; Z é fenila, naftila, hetero arila ou hetero arila fundido a fenila onde a porção heteroarila contem 5-6 átomos de anel, e 1-3 heteroátomos selecionados de nitrogênio, oxigênio, ou enxofre; onde as porções fenila, naftila, heteroarila, ou fenila fundida a heteroarila podem estar opcionalmente mono-, di-, ou tri-substituído com R^ 1^; R^ 1^ é hidrogênio, halogênio, alquila de 1-8 átomos de carbono, alquenila de 2-6 átomos de carbono, alquinila de 2-6 átomos de carbono, ciclo alquila de 3-6 átomos de carbono, -(CH~ 2~)~ n~Z, -OR^ 2^, -CN, -COR^ 2^, perflúor alquila de 1-4 átomos de carbono, -CONR^ 2^R^ 3^, -S(O)~ x~R^ 2^-OPO(OR^ 2^)OR^ 3^, -PO(OR^ 2^)R^ 3^, -OC(O)NR^ 2^R~ 3~,-COOR^ 2^, -CONR^ 2^R^3^, -SO~ 3~H, -NR^ 2^R^ 3^, -NR^ 3^COR^ 3^, -NR^ 2^COOR^ 3^, -SO~ 2~NR^ 2^R^ 2^, -NR^ 2^CONR^ 2^R^ 3^,-NR^ 2^C(=NR^ 3^)NR^ 2^R^ 3^, -SO~ 2~NHCOR^ 4^, -CONHSO~ 2~R^ 4^, -tetrazol-5-ila, -SO~ 2~NHCN, -SO~ 2~NHCONR^ 2^R^ 3^, ou Z; V é um anel hetero ciclo alquila saturado ou parcialmente insaturado de 5-7 átomos de anel tendo 1-3 heteroátomos selecionados de N, O ou S, que pode estar opcionalmente mono-, ou di-substituido com R^ 2^; R^ 2^ e R^ 3^ são cada, independentemente, hidrogênio, alquila de 1-8 átomos de carbono, alquenila de 3-6 átomos de carbono, alquinila de 2-6 átomos de carbono, ciclo alquila de 2-6 átomos de carbono, perflúor alquila de 1-4 átomos de carbono, Z ou V; R^ 4^ é alquila de 1-8 átomos de carbono, alquenila de 2-6 átomos de carbono, alquinila de 2-6 átomos de carbono, ciclo alquila de 3-6 átomos de carbono; perflúor alquila de 1-4 átomos de carbono, Z ou V; R^ 5^ é hidrogênio, alquila de 1-8 átomos de carbono, alquenila de 2-6 átomos de carbono, alquinila de 2-6 átomos de carbono, Z, ou V; N = 1-6; x = 0-2 ou um seu sal farmaceuticamente aceitável.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US94418897A | 1997-10-06 | 1997-10-06 | |
| US5585698A | 1998-04-06 | 1998-04-06 | |
| PCT/US1998/007380 WO1999018076A1 (en) | 1997-10-06 | 1998-04-14 | The preparation and use of ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloproteinase and tace inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR9812727A true BR9812727A (pt) | 2000-08-22 |
Family
ID=26734697
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR9812727-6A BR9812727A (pt) | 1997-10-06 | 1998-04-14 | Preparação e uso de ácidos orto-sulfonamido bicìclico hetero aril hidroxâmicos como metalo proteinase matriz e inibidores de tace |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP1021413B1 (pt) |
| JP (1) | JP2003520183A (pt) |
| KR (1) | KR20010030935A (pt) |
| CN (1) | CN1138760C (pt) |
| AT (1) | ATE242768T1 (pt) |
| AU (1) | AU760218B2 (pt) |
| BR (1) | BR9812727A (pt) |
| CA (1) | CA2303449A1 (pt) |
| DE (1) | DE69815544T2 (pt) |
| DK (1) | DK1021413T3 (pt) |
| ES (1) | ES2200335T3 (pt) |
| HU (1) | HUP0003880A3 (pt) |
| IL (1) | IL135105A0 (pt) |
| NO (1) | NO20001755L (pt) |
| NZ (1) | NZ503637A (pt) |
| PL (1) | PL339730A1 (pt) |
| PT (1) | PT1021413E (pt) |
| RU (1) | RU2202546C2 (pt) |
| WO (1) | WO1999018076A1 (pt) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR035478A1 (es) * | 1999-01-27 | 2004-06-02 | Wyeth Corp | Acido amida-hidroxamico, acido acetilenico, beta-sulfonamido y fosfinico como inhibidores de la tace, uso de los mismos para la manufactura de un medicamento y composicion farmaceutica que los contiene |
| US6326516B1 (en) | 1999-01-27 | 2001-12-04 | American Cyanamid Company | Acetylenic β-sulfonamido and phosphinic acid amide hydroxamic acid TACE inhibitors |
| TW589181B (en) * | 2001-09-05 | 2004-06-01 | Eisai Co Ltd | Lymphocytic activation inhibitor and remedial agent for autoimmune disease |
| MXPA04010441A (es) | 2002-04-23 | 2005-02-14 | Shionogi & Co | Derivado de pirazolo[1,5-a]pirimidina e inhibidor de nad(p)h oxidasa que contiene el mismo. |
| TW200418825A (en) | 2002-12-16 | 2004-10-01 | Hoffmann La Roche | Novel (R)-and (S) enantiomers of thiophene hydroxamic acid derivatives |
| EA018670B9 (ru) * | 2007-03-14 | 2014-01-30 | Ранбакси Лабораториз Лимитед | Производные пиразоло[3,4-в]пиридина в качестве ингибиторов фосфодиэстеразы |
| JP5588339B2 (ja) * | 2007-06-25 | 2014-09-10 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規化学化合物 |
| WO2011146591A1 (en) | 2010-05-19 | 2011-11-24 | Millennium Pharmaceuticals, Inc. | Substituted hydroxamic acids and uses thereof |
| AU2019352741A1 (en) | 2018-10-04 | 2021-05-06 | Assistance Publique-Hôpitaux De Paris (Aphp) | EGFR inhibitors for treating keratodermas |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE213232T1 (de) * | 1995-11-13 | 2002-02-15 | Hoechst Ag | Cyclische und heterocyclische n-substituierte alpha-iminohydroxam- und carbonsäuren |
| FR2748026B1 (fr) * | 1996-04-26 | 1998-06-05 | Adir | Nouveaux inhibiteurs de metalloproteases, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| AU743901B2 (en) * | 1996-10-16 | 2002-02-07 | Wyeth Holdings Corporation | Ortho-sulfonamido bicyclic heteroaryl hydroxamic acids as matrix metalloprote inase and tace inhibitors |
-
1998
- 1998-04-14 ES ES98915523T patent/ES2200335T3/es not_active Expired - Lifetime
- 1998-04-14 RU RU2000111469/04A patent/RU2202546C2/ru not_active IP Right Cessation
- 1998-04-14 DK DK98915523T patent/DK1021413T3/da active
- 1998-04-14 WO PCT/US1998/007380 patent/WO1999018076A1/en active IP Right Grant
- 1998-04-14 AU AU69685/98A patent/AU760218B2/en not_active Ceased
- 1998-04-14 PL PL98339730A patent/PL339730A1/xx unknown
- 1998-04-14 NZ NZ503637A patent/NZ503637A/xx unknown
- 1998-04-14 CA CA002303449A patent/CA2303449A1/en not_active Abandoned
- 1998-04-14 AT AT98915523T patent/ATE242768T1/de not_active IP Right Cessation
- 1998-04-14 CN CNB988117630A patent/CN1138760C/zh not_active Expired - Fee Related
- 1998-04-14 DE DE69815544T patent/DE69815544T2/de not_active Expired - Fee Related
- 1998-04-14 BR BR9812727-6A patent/BR9812727A/pt not_active Application Discontinuation
- 1998-04-14 PT PT98915523T patent/PT1021413E/pt unknown
- 1998-04-14 IL IL13510598A patent/IL135105A0/xx unknown
- 1998-04-14 HU HU0003880A patent/HUP0003880A3/hu unknown
- 1998-04-14 JP JP2000514888A patent/JP2003520183A/ja active Pending
- 1998-04-14 EP EP98915523A patent/EP1021413B1/en not_active Expired - Lifetime
- 1998-04-14 KR KR1020007003657A patent/KR20010030935A/ko not_active Application Discontinuation
-
2000
- 2000-04-05 NO NO20001755A patent/NO20001755L/no unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN1138760C (zh) | 2004-02-18 |
| PL339730A1 (en) | 2001-01-02 |
| NZ503637A (en) | 2002-10-25 |
| AU760218B2 (en) | 2003-05-08 |
| KR20010030935A (ko) | 2001-04-16 |
| CA2303449A1 (en) | 1999-04-15 |
| IL135105A0 (en) | 2001-05-20 |
| HUP0003880A3 (en) | 2001-11-28 |
| PT1021413E (pt) | 2003-10-31 |
| EP1021413B1 (en) | 2003-06-11 |
| NO20001755L (no) | 2000-05-31 |
| JP2003520183A (ja) | 2003-07-02 |
| CN1280568A (zh) | 2001-01-17 |
| DE69815544D1 (de) | 2003-07-17 |
| RU2202546C2 (ru) | 2003-04-20 |
| EP1021413A1 (en) | 2000-07-26 |
| NO20001755D0 (no) | 2000-04-05 |
| HUP0003880A2 (hu) | 2001-04-28 |
| AU6968598A (en) | 1999-04-27 |
| DE69815544T2 (de) | 2004-05-13 |
| ES2200335T3 (es) | 2004-03-01 |
| WO1999018076A1 (en) | 1999-04-15 |
| ATE242768T1 (de) | 2003-06-15 |
| DK1021413T3 (da) | 2003-10-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR9812727A (pt) | Preparação e uso de ácidos orto-sulfonamido bicìclico hetero aril hidroxâmicos como metalo proteinase matriz e inibidores de tace | |
| EA200200619A1 (ru) | Непептидильные ингибиторы vla-4-зависимого связывания клеток, применяемые при лечении воспалительных, аутоимунных и респираторных заболеваний | |
| DK157730C (da) | Fremgangsmaade til fremstilling af et farmaceutisk mikrokapselpraeparat og praeparat fremstillet ved fremgangsmaaden | |
| NO171005C (no) | Fremgangsmaate for fremstilling av et vandig flytende preparat | |
| FI883837A0 (fi) | Aoksjuka foerhindrande komposition. | |
| BR9713105A (pt) | Uso para os derivados de 1,3 - propanodiol | |
| EA200100204A1 (ru) | Фармацевтические агенты для лечения болезни паркинсона, ганв и микроаденом | |
| NO904114L (no) | Pyrimidin-4,6-dikarboksylsyrediamider samt fremgangsmaate for fremstilling derav. | |
| KR890011895A (ko) | 세팔로스포린 염 및 주사용 조성물 | |
| MX9204637A (es) | Nuevos derivados de pirazina y procedimiento para su preparacion. | |
| ES528088A0 (es) | Procedimiento de preparacion de nuevos derivados de tieno (2,3-b) pirrol. | |
| ES508343A0 (es) | "procedimiento para la preparacion de nuevas pirimido (5,4-d) pirimidinas trisustituidas". | |
| DK282285A (da) | Hidtil ukendte 8-alkylthio-2-piperazino-pyrimido(5,4-d)pyrimidiner,deres fremstilling og laegemidler indeholdende disse forbindelser | |
| PT99970A (pt) | Processo e intermediarios para a preparacao de azabiciclo {2.2.2.} octan-3-iminas | |
| MX9204179A (es) | Derivados de imidazo(2,1-b)benzotiazola-3-acetamida, su preparacion y su aplicacion en terapeutica. | |
| BR0108845A (pt) | 4-hidroxi-1,8-naftiridina-3-carboxamidas como agentes antivirais | |
| ES519606A0 (es) | Procedimiento para la preparacion de nuevas piridobenzodiazepinonas. | |
| DK1068209T3 (da) | Fremgangsmåde til fremstilling af purinderivater og deres mellemprodukter | |
| ES2038700T3 (es) | Procedimiento para la obtencion de alilmercaptoacetil-sidnoniminas. | |
| FI845102L (fi) | Imidazo/1,2-c/pyrimidiner. | |
| ES506103A0 (es) | Procedimiento para la preparacion de 2-fenilamino-imidazoli-nas-(2) sustituidas | |
| PT96757A (pt) | Processo de preparacao de derivados de indolo e de composicoes farmaceuticas | |
| ES505896A0 (es) | Procedimiento para la obtencion de nuevos derivados de la tiazolo (3,2-a)pirimidina | |
| BR0109487A (pt) | 4-oxo-1,4-dihidro-3-cinolinacarboxamidas como agentes antivirais | |
| ES499864A0 (es) | Procedimiento para la preparacion de nuevas cefalosporinas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B25D | Requested change of name of applicant approved |
Owner name: WYETH HOLDINGS CORPORATION (US) Free format text: ALTERADO DE: AMERICAN CYANAMID COMPANY |
|
| B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |